Patent · US Active

Compositions and methods for inhibiting viral replication

US7745418B2 · kind B2 · utility

4Cited by

3References

28Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Matthias John · Hallstadt, DE
Stefan Limmer · Neudrossenfeld, DE
Hans-Peter Vornlocher · Bayreuth, DE
Roland Kreutzer · Weidenberg, DE

Key dates

Filing date	Dec 19, 2007
Grant date	Jun 29, 2010
Priority date	—
Expiry date	Jun 9, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/53
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.